Waldemar Priebe
Affiliations: | Experimental Therapeutics | University of Texas MD Anderson Cancer Center, Houston, TX, United States |
Area:
drug designWebsite:
https://faculty.mdanderson.org/profiles/waldemar_priebe.htmlGoogle:
"Waldemar Priebe"Bio:
DOI: 10.1016/S0008-6215(00)85593-7
Mean distance: (not calculated yet)
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sharma P, Roberts C, Herpai D, et al. (2020) Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel, Switzerland). 13 |
| Zielinski R, Grela K, Skora S, et al. (2020) Abstract P2-15-03: Liposomal annamycin inhibition of lung localized breast cancer Cancer Research. 80 |
| Zielinski R, Grela K, Skora S, et al. (2019) Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model Blood. 134: 5150-5150 |
| Zielinski R, Fokt I, Skora S, et al. (2019) Abstract 4799: Inhibition of STAT3 in pancreatic ductal adenocarcinoma and immunotherapeutic implications Cancer Research. 79: 4799-4799 |
| Zielinski R, Zal T, Grela K, et al. (2019) Abstract C094: Dose and schedule-dependent efficacy of liposomal Annamycin in pre-clinical models of acute myeloid leukemia Molecular Cancer Therapeutics. 18 |
| Basu H, Wilganowski N, Lieblich J, et al. (2018) Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer Cancer Research. 78 |
| Basu HS, Wilgonowski NL, Lieblich JL, et al. (2018) Abstract 3846: A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer Cancer Research. 78: 3846-3846 |
| Olbryt M, Rusin A, Fokt I, et al. (2017) Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Investigational New Drugs. 35: 545-555 |
| Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, et al. (2016) MODELING STROMA-INDUCED DRUG RESISTANCE IN A TISSUE-ENGINEERED TUMOR MODEL OF EWING SARCOMA. Tissue Engineering. Part A |
| Shingu T, Holmes L, Henry V, et al. (2016) Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Journal of Translational Medicine. 14: 46 |